Percutaneous Treatment of Tricuspid Regurgitation With the Novel TriFlO® Device: First in Human Italian Experience

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Abbott
• Equity/Stock(s)/Options - TRIFLO Cardiovascular